Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

Docirbrutinib (AS-1763), a novel non-COVALENT pan-mutant BTK inhibitor, demonstrates durable clinical responses in patients with previously treated B-cell malignancies: Data from an ongoing Phase 1b study

Nitin Jain, Catherine Coombs, James D'Olimpio, Nirav Shah, Jacqueline Barrientos, Seung Tae Lee, Danielle Brander, John Nemunaitis, Andrew Gillis-Smith, Shuo Ma, Shirou Kirita, Koji Yoshida, Masaaki Sawa, Kyoko Miyamoto, Akinori Arimura, William Wierda, Varsha Gandhi, Javier Pinilla-Ibarz

Blood (2025) 146 (Supplement 1): 3892.

https://doi.org/10.1182/blood-2025-3892

Published: 2025

Journal Articles

Hodgkin lymphoma-driven hemophagocytic lymphohistiocytosis (HLH) in a predominantly hispanic cohort: A multicenter analysis of clinical features and treatment outcomes

Mitchell Boshkos, Kelly Meza, Humberto Nieves Jimenez, Carla Romagnoli, Alexandra Lyubimova, Jacqueline Barrientos, Martha Mims

Blood (2025) 146 (Supplement 1): 2980.

https://doi.org/10.1182/blood-2025-2980

Published: 2025

Journal Articles

Racial and socioeconomic disparities in clinical trial participation and outcomes in systemic peripheral T-cell lymphoma (PTCL): A multicenter retrospective Study

Blood (2025) 146 (Supplement 1): 4523.

https://doi.org/10.1182/blood-2025-4523

Published: 2025

Journal Articles

Machine learning–based detection model for leukemia cells in peripheral blood smears using YOLOv11-large

Johan Diaz, Arunima Deb, Alexandra Lyubimova, Leily Santos-Carrion, Carla Romagnoli, Jacqueline Barrientos

Blood (2025) 146 (Supplement 1): 6123.

https://doi.org/10.1182/blood-2025-6123

Published: 2025

Journal Articles

Dose and BTK occupancy relationship in the prospective Phase 2 TAILOR study: Exploratory end point analysis of the ibrutinib monotherapy cohorts in patients with previously untreated chronic lymphocytic leukemia

Blood (2025) 146 (Supplement 1): 3301.

https://doi.org/10.1182/blood-2025-3301

Published: 2025

Journal Articles

primary breast lymphoma: A 10-year retrospective case series on clinical features, diagnostic imaging, and outcomes from a diverse population treated at mount sinai medical center in miami beach

Carla Romagnoli, Leily Santos-Carrion, Alexandra Lyubimova, Evelyn Goya Balaguer, Oleg Gligich, Michael Schwartz, Mike Cusnir, Jacqueline Barrientos

Blood (2025) 146 (Supplement 1): 8105.

https://doi.org/10.1182/blood-2025-8105

Published: 2025

Journal Articles

Mediators of racial and ethnic inequities in access to front-line therapies for chronic lymphocytic leukemia in the United States: A real-world evidence study

Joanna Rhodes, Adam Kittai, Paul Hampel, Xiaoliang Wang, Qianhong Fu, Danni Zhao, Smriti Karwa, Olive Mbah, Ahmed Sawas, Benjamin Wagner, Rachel Myers, Derrick van Beuge, Gregory Maglinte, Erlene Seymour, Jacqueline Barrientos

Blood (2025) 146 (Supplement 1): 2720.

https://doi.org/10.1182/blood-2025-2720

Published: 2025

Journal Articles

Tailor: Interventional Study Evaluating Physician's Choice of Ibrutinib Monotherapy or Ibrutinib-Venetoclax Combination Using Dose Modifications and Alternate Dosing Approaches in Patients with Untreated Chronic Lymphocytic Leukemia

Jeff P. Sharman, Jan A. Burger, Jacqueline Barrientos, Philip Kuruvilla, Sima Patel, Gabriel Krigsfeld, Sowmya Srikanthan, Bothayna Messahel, Wasiulla Khan, Emma Smith, Paolo Ghia

Blood (2023) 142 (Supplement 1): 6564.

https://doi.org/10.1182/blood-2023-174751

Published: 2023

Journal Articles

Long-term outcomes for ibrutinib–rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial

Blood (2022) 140 (2): 112–120.

https://doi.org/10.1182/blood.2021014960

Published: 2022

Includes: Supplemental data

Journal Articles

First-Line Treatment with Ibrutinib (Ibr) Plus Venetoclax (Ven) for Chronic Lymphocytic Leukemia (CLL): 2-Year Post-Randomization Disease-Free Survival (DFS) Results from the Minimal Residual Disease (MRD) Cohort of the Phase 2 Captivate Study

Paolo Ghia, John N. Allan, Tanya Siddiqi, Thomas J. Kipps, Bryone J. Kuss, Stephen Opat, Ian W. Flinn, Xavier C. Badoux, Alessandra Tedeschi, Eva Gonzalez-Barca, John M. Pagel, Ryan Jacobs, Jacqueline Barrientos, Edith Szafer-Glusman, Cathy Zhou, Joi Ninomoto, James P. Dean, Constantine S. Tam, William G. Wierda

Blood (2021) 138 (Supplement 1): 68.

https://doi.org/10.1182/blood-2021-144544

Published: 2021

Journal Articles

Analyses of the Kinetics and Phenotype of Multiple Intraclonal CXCR4/CD5 B Cell Subsets Suggest Differences in Life Cycle Transitioning in CLL

Andrea Nicola Mazzarello, Mark Fitch, Anita Ng, Sabreen Bhuiya, Esha Sharma, Andrew Shih, Martina Cardillo, Steven L Allen, Jonathan E Kolitz, Jacqueline Barrientos, Kanti R Rai, Marc Hellerstein, Nicholas Chiorazzi

Blood (2021) 138 (Supplement 1): 2622.

https://doi.org/10.1182/blood-2021-154224

Published: 2021

Journal Articles

Serum Proteomic Analyses Suggest That the HMGB1 and Other Inflammatory Pathways Are Operational in MBL and Are Less in Overt CLL

Florencia Palacios, Gonzalo Blanco, Kamala Vanarsa, Poojitha Dugyala, Steven L Allen, Yasmine Kieso, Anna Puiggros, Jacqueline Barrientos, Xavier Calvo, Jonathan E Kolitz, Eva Gimeno, Joanna M Rhodes, ANA Ferrer, Kanti R Rai, Blanca Espinet, Chandra Mohan, Nicholas Chiorazzi

Blood (2021) 138 (Supplement 1): 2625.

https://doi.org/10.1182/blood-2021-152514

Published: 2021

Journal Articles

Phase 1 Dose Escalation and Cohort Expansion Study of the Anti-ROR1 Antibody-Drug Conjugate Zilovertamab Vedotin (MK-2140) for the Treatment of Non-Hodgkin Lymphoma

Michael Wang, Matthew Mei, Paul M. Barr, Jacqueline Barrientos, Sven de Vos, Richard Furman, Krish Patel, Philip A. Thompson, Michael Choi, Avyakta Kallam, Ying Zhu, Samhita Chakraborty, Patricia Marinello, Stephen E. Spurgeon

Blood (2021) 138 (Supplement 1): 528.

https://doi.org/10.1182/blood-2021-148607

Published: 2021

Journal Articles

Ibrutinib Combined with Obinutuzumab and CHOP (I-OCHOP) for Richter Transformation

Carlos A Lopez, Vernon Wu, Joanna M Rhodes, Kanti R Rai, Jacqueline Barrientos

Blood (2021) 138 (Supplement 1): 4698.

https://doi.org/10.1182/blood-2021-153947

Published: 2021

Journal Articles

Quality of Life in Patients <=70 Years of Age with Chronic Lymphocytic Leukemia Treated Frontline with Ibrutinib-Rituximab Versus Fludarabine Cyclophosphamide Rituximab: Analysis from ECOG-ACRIN E1912

Blood (2021) 138 (Supplement 1): 1562.

https://doi.org/10.1182/blood-2021-150462

Published: 2021

Journal Articles

Clinical Outcomes of Low Histologic Grade Follicular Lymphoma with High Proliferation Index

Vernon Wu, Muhammed A Salyana, Mohammed Abdelwahed, Jacqueline Barrientos, Steven L Allen, Jonathan E Kolitz, Kristin Sticco, Joanna M Rhodes

Blood (2021) 138 (Supplement 1): 3552.

https://doi.org/10.1182/blood-2021-149525

Published: 2021

Journal Articles

Phase 1b/2 Study of Cirmtuzumab and Ibrutinib in Mantle Cell Lymphoma (MCL) or Chronic Lymphocytic Leukemia (CLL)

Hun Ju Lee, Michael Choi, Tanya Siddiqi, Jacqueline Barrientos, William G. Wierda, Iris Isufi, Joseph Tuscano, Nicole Lamanna, Suki Subbiah, Jean L. Koff, Lori A. Leslie, Alec Goldenberg, Gina G Chung, James B. Breitmeyer, Salim Yazji, Yao Wang, Michael Wang, Catriona Jamieson, Thomas J. Kipps

Blood (2021) 138 (Supplement 1): 3534.

https://doi.org/10.1182/blood-2021-148779

Published: 2021

Journal Articles

Efficacy of Ibrutinib Monotherapy in Pre-Clinical Mouse Models of Richter Transformation: Ibrutinib Effectively Reduces the Incidence of Richter Transformation but Fails in Treating Transformed Lymphoma, Especially in Primary Lymphoid Tissue

Shih-Shih Chen, Jacqueline Barrientos, Xiao-Jie Yan, Uwe Wirtz, Edith Szafer-Glusman, Kanti R Rai, Nicholas Chiorazzi

Blood (2021) 138 (Supplement 1): 3708.

https://doi.org/10.1182/blood-2021-153685

Published: 2021

Journal Articles

Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: updated phase 2 results

Blood (2020) 135 (15): 1204–1213.

https://doi.org/10.1182/blood.2018884940

Published: 2020

Includes: Supplemental data

Journal Articles

Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia

Blood (2017) 129 (5): 553–560.

https://doi.org/10.1182/blood-2016-01-689422

Published: 2017

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Docirbrutinib (AS-1763), a novel non-COVALENT pan-mutant BTK inhibitor, demonstrates durable clinical responses in patients with previously treated B-cell malignancies: Data from an ongoing Phase 1b study

Hodgkin lymphoma-driven hemophagocytic lymphohistiocytosis (HLH) in a predominantly hispanic cohort: A multicenter analysis of clinical features and treatment outcomes

Racial and socioeconomic disparities in clinical trial participation and outcomes in systemic peripheral T-cell lymphoma (PTCL): A multicenter retrospective Study

Machine learning–based detection model for leukemia cells in peripheral blood smears using YOLOv11-large

Dose and BTK occupancy relationship in the prospective Phase 2 TAILOR study: Exploratory end point analysis of the ibrutinib monotherapy cohorts in patients with previously untreated chronic lymphocytic leukemia

primary breast lymphoma: A 10-year retrospective case series on clinical features, diagnostic imaging, and outcomes from a diverse population treated at mount sinai medical center in miami beach

Mediators of racial and ethnic inequities in access to front-line therapies for chronic lymphocytic leukemia in the United States: A real-world evidence study

Tailor: Interventional Study Evaluating Physician's Choice of Ibrutinib Monotherapy or Ibrutinib-Venetoclax Combination Using Dose Modifications and Alternate Dosing Approaches in Patients with Untreated Chronic Lymphocytic Leukemia

Long-term outcomes for ibrutinib–rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial

First-Line Treatment with Ibrutinib (Ibr) Plus Venetoclax (Ven) for Chronic Lymphocytic Leukemia (CLL): 2-Year Post-Randomization Disease-Free Survival (DFS) Results from the Minimal Residual Disease (MRD) Cohort of the Phase 2 Captivate Study

Analyses of the Kinetics and Phenotype of Multiple Intraclonal CXCR4/CD5 B Cell Subsets Suggest Differences in Life Cycle Transitioning in CLL

Serum Proteomic Analyses Suggest That the HMGB1 and Other Inflammatory Pathways Are Operational in MBL and Are Less in Overt CLL

Phase 1 Dose Escalation and Cohort Expansion Study of the Anti-ROR1 Antibody-Drug Conjugate Zilovertamab Vedotin (MK-2140) for the Treatment of Non-Hodgkin Lymphoma

Ibrutinib Combined with Obinutuzumab and CHOP (I-OCHOP) for Richter Transformation

Quality of Life in Patients <=70 Years of Age with Chronic Lymphocytic Leukemia Treated Frontline with Ibrutinib-Rituximab Versus Fludarabine Cyclophosphamide Rituximab: Analysis from ECOG-ACRIN E1912

Clinical Outcomes of Low Histologic Grade Follicular Lymphoma with High Proliferation Index

Phase 1b/2 Study of Cirmtuzumab and Ibrutinib in Mantle Cell Lymphoma (MCL) or Chronic Lymphocytic Leukemia (CLL)

Efficacy of Ibrutinib Monotherapy in Pre-Clinical Mouse Models of Richter Transformation: Ibrutinib Effectively Reduces the Incidence of Richter Transformation but Fails in Treating Transformed Lymphoma, Especially in Primary Lymphoid Tissue

Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: updated phase 2 results

Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only